Genomma Lab InternacionalB de CV (FRA:GEKA) Cyclically Adjusted Revenue per Share: €0.88 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GEKA Genomma Lab Internacional SAB de CV FRA:GEKA
57 GF Score
Price €0.62
GF Value €0.86
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share?

Genomma Lab InternacionalB de CV FRA:GEKA -0.80% 57 Cyclically Adjusted Revenue per Share is €0.88 as of Jun. 2026. GuruFocus rates FRA:GEKA with a GF Score™ of 57/100 and a GF Value™ of €0.86 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genomma Lab InternacionalB de CV's adjusted revenue per share for the three months ended in Jun. 2026 was €0.223. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.88 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genomma Lab InternacionalB de CV's average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genomma Lab InternacionalB de CV was 9.10% per year. The lowest was 4.70% per year. And the median was 8.20% per year.

As of today (2026-09-16), Genomma Lab InternacionalB de CV's current stock price is €0.62. Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.88. Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio of today is 0.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genomma Lab InternacionalB de CV was 1.86. The lowest was 0.69. And the median was 1.31.


Genomma Lab InternacionalB de CV  (FRA:GEKA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.62/0.878
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genomma Lab InternacionalB de CV was 1.86. The lowest was 0.69. And the median was 1.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Related Terms


Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.72 0.77 0.80 0.83 0.84

Genomma Lab InternacionalB de CV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.86 0.87 0.88 0.88

FRA:GEKA vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio falls into.


FRA:GEKA
57GF Score
Genomma Lab Internacional SAB de CV FRA:GEKA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genomma Lab InternacionalB de CV's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.223/165.5700*165.5700
=0.223

Current CPI (Jun. 2026) = 165.5700.

Genomma Lab InternacionalB de CV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.144 103.084 0.231
201612 0.134 105.002 0.211
201703 0.156 108.063 0.239
201706 0.150 108.339 0.229
201709 0.155 109.628 0.234
201712 0.136 112.114 0.201
201803 0.129 113.505 0.188
201806 0.133 113.373 0.194
201809 0.131 115.130 0.188
201812 0.136 117.530 0.192
201903 0.142 118.050 0.199
201906 0.150 117.848 0.211
201909 0.141 118.581 0.197
201912 0.151 120.854 0.207
202003 0.149 121.885 0.202
202006 0.140 121.777 0.190
202009 0.131 123.341 0.176
202012 0.140 124.661 0.186
202103 0.143 127.574 0.186
202106 0.159 128.936 0.204
202109 0.168 130.742 0.213
202112 0.172 133.830 0.213
202203 0.173 137.082 0.209
202206 0.202 139.233 0.240
202209 0.214 142.116 0.249
202212 0.213 144.291 0.244
202303 0.217 146.472 0.245
202306 0.237 146.272 0.268
202309 0.248 148.446 0.277
202312 0.197 151.017 0.216
202403 0.241 152.947 0.261
202406 0.265 153.551 0.286
202409 0.259 155.246 0.276
202412 0.223 157.378 0.235
202503 0.210 158.761 0.219
202506 0.216 160.180 0.223
202509 0.209 161.030 0.215
202512 0.193 163.190 0.196
202603 0.209 166.040 0.208
202606 0.223 165.570 0.223

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.88 mean?
Genomma Lab InternacionalB de CV (FRA:GEKA) has a Cyclically Adjusted Revenue per Share of €0.88 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors.
Is Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share too high?
Genomma Lab InternacionalB de CV's current Cyclically Adjusted Revenue per Share is €0.88. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share of €0.88 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Cyclically Adjusted Revenue per Share is €0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (FRA:GEKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.86, compared to a current price of €0.62 — trading 27.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.88. Genomma Lab InternacionalB de CV's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (FRA:GEKA), the current Cyclically Adjusted Revenue per Share is €0.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (FRA:GEKA) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of €0.62 is trading 27.9% below its estimated GF Value™ of €0.86. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for FRA:GEKA:

  • Cyclically Adjusted Revenue per Share: €0.88
  • GF Value™: €0.86 vs. price of €0.62 (27.9% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:GEKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USALABB:Mexico
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
57GF Score

Get the complete analysis for FRA:GEKA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.62
Price
€0.86
GF Value